MRI Contrast Media Market Report 2026

MRI Contrast Media Market Overview

• MRI Contrast Media market size has reached to $1.66 billion in 2025 • Expected to grow to $2.15 billion in 2030 at a compound annual growth rate (CAGR) of 5% • Growth Driver: Rising Cancer Cases Fueling Growth Of MRI Contrast Media Market • Market Trend: Innovative Products Driving Advancements In MRI Contrast Media Market • North America was the largest region in 2025.

What Is Covered Under MRI Contrast Media Market?

MRI contrast media refer to substances used in magnetic resonance imaging (MRI) to enhance the visibility of internal body structures. These contrast agents work by altering the magnetic properties of tissues, thereby improving the contrast in the resulting images. The main MRI contrast media products are extracellular contrast agents, blood-pool agents, and hepatobiliary agents. Extracellular contrast agents are substances used in magnetic resonance imaging (MRI) to enhance the visibility of internal body structures. It is applied for neurological disorders, musculoskeletal disorders, cardiovascular disorders, cancer detection, and others by several end-users such as hospitals, diagnostic and imaging centers, research institutes, and others.

What Is The MRI Contrast Media Market Growth Forecast?

The mri contrast media market size is expected to see strong growth in the next few years. It will grow to $2.15 billion in 2030 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to expansion of cancer screening programs, adoption of novel mri contrast formulations, growth in outpatient imaging centers, rising investments in radiology r&d, increasing focus on safer contrast compositions. Major trends in the forecast period include increasing use of gadolinium-free contrast agents, rising adoption of nano-based contrast materials, expansion of contrast media safety monitoring protocols, growth in mri utilization for chronic disease diagnosis, development of organ-specific and targeted agents.

Global MRI Contrast Media Market Segmentation

1) By Product: Extracellular Contrast Agents, Blood-Pool Agent, Hepatobiliary Agents 2) By Application: Neurological Disorders, Musculoskeletal Disorders, Cardiovascular Disorders, Cancer Detection, Other Applications 3) By End-User: Hospitals, Diagnostic And Imaging Centers, Research Institutes, Other End Users Subsegments: 1) By Extracellular Contrast Agents: Gadolinium-Based Contrast Agents (GBCA), Non-Gadolinium-Based Contrast Agents 2) By Blood-Pool Agent: Macromolecular Agents, Nanoparticle-Based Agents 3) By Hepatobiliary Agents: Hepatocyte-Specific Agents, Biliary-Specific Agents

What Is The Driver Of The MRI Contrast Media Market?

The rise in cancer cases is expected to propel the growth of the MRI contrast media market going forward. The rise in cancer cases is multifactorial, influenced by a combination of demographic, lifestyle, environmental, genetic, and healthcare-related factors. Contrast agents containing gadolinium-based compounds, when administered during MRI scans, enhance visualization by altering tissue magnetic properties, aiding in the detection, sizing, and characterization of tumors, as well as assessing their invasion into surrounding tissues. For instance, in January 2024, according to the data published by the American Cancer Society, a US-based non-profit organization, the United States is projected to see 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, compared to 1,958,310 cases and 609,820 deaths in 2023. Therefore, the rise in cancer cases is driving the growth of the MRI contrast media industry.

Key Players In The Global MRI Contrast Media Market

Major companies operating in the mri contrast media market are Bayer AG, GE Healthcare Technologies Inc., Bracco S.p.A., Guerbet LLC, Lantheus Medical Imaging Inc., Fujifilm Holdings Corporation, Spago Nanomedical AB, Fresenius Kabi AG, Curium Pharma, Miltenyi Biotec B.V. & Co. KG, Polarean Inc., BioPAL Inc., Jiangsu Hengrui Pharmaceutical Co. Ltd., Trivitron Healthcare, Beijing Beilu Pharmaceuticals Company Limited, Taejoon Pharm Co. Ltd., Mediso USA LLC, Nano Therapeutics Pvt. Ltd., Eisai Co. Ltd., Daiichi Sankyo Company Limited, Maruishi Pharmaceutical Co. Ltd., Jodas Expoim Pvt Ltd, Lumiphore Inc., Naviscan Inc.

Global MRI Contrast Media Market Trends and Insights

Major companies operating in the MRI contrast media market are focusing on developing and distributing advanced products, such as macrocyclic gadolinium-based contrast agents (GBCA), to enhance the diagnostic capabilities and safety profile of MRI imaging procedures. A macrocyclic gadolinium-based contrast agent (GBCA) is a type of contrast agent used in medical imaging, particularly in magnetic resonance imaging (MRI). For instance, in February 2023, Guerbet, a France-based provider of MRI contrast media, launched the Elucirem (gadopiclenol) injection. The unique feature of Elucirem (gadopiclenol) injection lies in its highly stable macrocyclic gadolinium-based contrast agent (GBCA), which has the highest relaxivity in its class for MRI. This innovative formulation of gadopiclenol is particularly noteworthy for its ability to detect and visualize lesions with abnormal vascularity in various regions of the central nervous system (including the brain, spine, and associated tissues) as well as the body (encompassing the head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

What Are Latest Mergers And Acquisitions In The MRI Contrast Media Market?

In March 2023, Bracco Imaging S.p.A., an Italy-based healthcare company, acquired the remaining 49% stake in Bracco-Eisai Co. Ltd. for an undisclosed amount. The acquisition aims to enable a swift and adaptable response to the evolving healthcare industry landscape. Its goal is to achieve sustainable contributions to patients through the utilization of the products. Bracco-Eisai Co. Ltd. is a Japan-based provider of MRI contrast media.

Regional Outlook

North America was the largest region in the MRI contrast media market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the MRI Contrast Media Market?

The MRI contrast media market consists of sales of gadopentetate dimeglumine (Gd-DTPA), gadodiamide, diatrizoate, and gadoversetamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the MRI Contrast Media Market Report 2026?

The mri contrast media market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mri contrast media industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.